Skip to main content
ALEC
NASDAQ Life Sciences

Alector's GSK Collaboration Terminated After Drug Failures; Repays $10.4M Loan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.83
Mkt Cap
$203.176M
52W Low
$1.09
52W High
$3.4
52W Position info
68% above low
Off High info
46% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ALEC sits 68% above its 52-week low of $1.09.

Summary

Alector announced the termination of its collaboration agreement with GSK following the failure of two key drug candidates, latozinemab and nivisnebart, while also reporting the repayment of a $10.4 million loan.


Key Events · M&A and Partnerships · ALEC

  • GSK Collaboration Terminated

    Glaxo Wellcome UK Limited (GSK) provided written notice to terminate the Collaboration and License Agreement, effective January 2, 2027. This follows the failure of latozinemab in Phase 3 and nivisnebart in Phase 2 clinical trials.

  • Loan Repaid and Terminated

    Alector repaid in full and terminated a Loan and Security Agreement with Hercules Capital, Inc., totaling $10,428,827.77 in principal, accrued interest, and charges.


Analysis · ALEC · Life Sciences

The termination of the significant collaboration with GSK is a major setback for Alector, directly impacting its pipeline and future revenue potential after both latozinemab and nivisnebart failed clinical trials. While the repayment of a $10.4 million loan improves the balance sheet, it is overshadowed by the loss of a key partnership and the clinical failures that led to it, raising concerns about the company's long-term drug development strategy and financial viability.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALEC was trading at $1.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $203.2M. The 52-week trading range was $1.09 to $3.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALEC - Latest Insights

ALEC
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $2.26 info
Change: +$0.080 (+4%) info
Market Cap: $347.628M info
ALEC
Nov 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.16
Real-time Price: $2.26 info
Change: +$0.0992 (+5%) info
Market Cap: $347.628M info
ALEC
Oct 16, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.02
Real-time Price: $2.26 info
Change: +$0.240 (+12%) info
Market Cap: $347.628M info
ALEC
Oct 05, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.82
Real-time Price: $2.26 info
Change: +$0.4399 (+24%) info
Market Cap: $347.628M info
ALEC
Oct 05, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.37
Real-time Price: $2.26 info
Change: -$0.110 (-5%) info
Market Cap: $347.628M info